Diode Laser Ablation for Threshold Retinopathy of Prematurity

Short-term Structural Outcome

Mitchell H. DeJonge, MD; Philip J. Ferrone, MD; Michael T. Trese, MD

Objective: To describe short-term structural outcomes and associated ocular complications in premature infants treated with diode laser ablation for retinopathy of prematurity.

Methods: The records of all infants who were diagnosed as having threshold retinopathy of prematurity and treated with diode laser therapy at our hospital from January 1, 1992, through December 31, 1996, were retrospectively reviewed. Sixty-four eyes reached threshold during this period. Three eyes received cryotherapy in addition to laser treatment and were excluded, leaving 61 eyes eligible for review.

Results: Of the 61 eyes with threshold disease treated exclusively with diode laser, 4 (7%) had zone I disease and 57 (93%) had zone II disease at the time of initial laser treatment. Three (5%) of the 61 eyes progressed to stage 4 disease (2 eyes, stage 4A; 1 eye, stage 4B). There were no cataracts or other ocular complications noted secondary to laser treatment based on short-term follow-up (mean follow-up, 120 days).

Conclusion: In this population of infants, diode laser ablation appears to be a safe and effective treatment for threshold retinopathy of prematurity.


See also page 438

RETINOPATHY of prematurity (ROP) is a well-documented morbidity in very low-birth-weight infants. The goal of therapy once an infant has developed threshold ROP is to prevent retinal detachment and to optimize long-term visual outcome. The multicenter study of cryotherapy for ROP (Cryo-ROP) documented that cryotherapy is an effective treatment to prevent the progression of ROP beyond threshold. However, the study also reported significant ocular and hemodynamic complications related directly to the traumatic nature of the application of cryotherapy. Due in part to these complications and to the technical difficulty of posterior cryotherapy application, laser ablation has now gained acceptance as an alternative to cryotherapy. Gold recently reported that 71% of ophthalmologists who treat ROP now use either argon or diode laser as their preferred method of treatment.

Despite their widespread use in the treatment of ROP, neither diode nor argon laser therapy has been studied extensively. Reports detailing small series of patients treated exclusively with diode laser therapy have indicated that it appears to be at least as effective as cryotherapy in stopping the progression of ROP beyond threshold. Likewise, argon laser therapy has also been reported to be effective in the treatment of threshold ROP. Of concern, however, are several reports that have noted the development of cataracts following both argon and diode laser ablation. Because of these reports and the need for continued investigation into laser therapy for ROP, we retrospectively evaluated our 5-year experience with diode laser ablation to determine the rate of progression beyond threshold ROP and to detail any associated short-term ocular complications.

RESULTS

The baseline characteristics of the 33 study patients (61 eyes) are listed in the Table. Between 1992 and 1996, 64 eyes (including the 3 eyes excluded from further study due to cryotherapy) progressed to threshold. This represents 10.8% of all eyes of 296 infants born weighing less than...
The mean number of laser burns applied to each affected eye per session was 580. Forty-eight eyes required 1 laser treatment each, 10 eyes required 2 treatments, and 3 eyes required 3 treatments. Three (5%) of the 61 eyes progressed to partial retinal detachment (2 eyes, stage 4A; 1 eye, stage 4B). These 3 patients (a single eye was involved in each patient) did not differ statistically from the rest of the group in terms of birth weight (639 ± 42 g), gestational age at birth (24.3 ± 0.6 weeks), or postconceptional age at initial treatment (37.7 ± 0.5 weeks). The 3 eyes that progressed all had zone II disease with 5 clock hours of stage 3 ROP at the time of initial laser treatment. The 2 eyes with stage 4A disease had been treated once with laser, the eye with stage 4B disease had received 2 laser treatments. The 2 eyes with stage 4A disease had their retinas completely reattached with lens-sparing vitrectomies. The eye with stage 4B disease also had its retina reattached with a lens-sparing vitrectomy; however, there was a residual superior retinal fold and a dragged macula postoperatively.

One eye had a visually insignificant cataract present prior to laser surgery, which did not worsen following laser treatment. No cataracts were seen in the other treated eyes during the follow-up period.

After the results of the Cryo-ROP study were published in 1988, cryotherapy became the standard of care for threshold ROP. However, since that landmark study, laser ablation has increasingly become the therapy of choice for threshold ROP. The increased use of laser can be attributed to 3 factors: (1) laser treatment requires less manipulation of the eye, (2) it is less traumatic to the patient; and (3) it is technically easier to apply when the disease is posterior. Unlike cryotherapy, it is unlikely that laser will be evaluated by a prospective randomized trial. Therefore, retrospective reviews and small clinical trials must continue to be performed and reported in an attempt to evaluate the safety and efficacy of diode laser therapy for ROP.

Because cryotherapy currently is the criterion standard against which all other ROP treatments are measured, we compared results of our patient population with those of the Cryo-ROP study. In our patients, the mean gestational age and birth weights were lower than those of infants in the Cryo-ROP study (24.5 ± 1.4 weeks vs 26.3 ± 1.9 weeks and 671 ± 168 g vs 800 ± 165 g, respectively) but the chronicologic age at which threshold was reached was similar (36.9 vs 37.2 weeks). Our infants...
had, on average, fewer affected clock hours than infants in the Cryo-ROP study (6.3 vs 9.6). Of the 61 eyes treated with diode laser therapy, 3 progressed to stage 4 disease. One of these eyes (2% of all treated eyes) progressed to stage 4B disease—an “unfavorable outcome” by the Cryo-ROP definition. By comparison, the Cryo-ROP study had an unfavorable outcome in 23.5% of the treated eyes.1

We recognize the potential for bias where noncontemporaneous studies are compared. Standard neonatal intensive care unit care including ventilator management, the use of surfactant, and the use of antenatal and postnatal steroids have changed dramatically over the past 10 years. An increase in survival of extremely low-birthweight infants has resulted in the development of retinopathy in infants who previously would not have lived. However, if anything, this would increase the risk of complications, which is contrary to what was found. In addition to a change in patient population, a shift in “severity bias” may now exist given the positive results of the treatment eyes in the Cryo-ROP study. As Palmer13 suggests, this shift in severity bias may lead to treatment of eyes with marginal threshold disease, eyes that might be expected to resolve spontaneously. This would spuriously improve the results of treatment.13 Our laser-treated infants had fewer affected clock hours than those in the Cryo-ROP study. The significance of this difference with regard to treatment outcome is unknown.

Recently, concerns have been raised about the formation of cataracts following laser therapy.9-12 Cryotherapy was not shown to be associated with cataracts in the Cryo-ROP study.1 In the present series, 1 child did have a small, visually insignificant cataract present prior to laser treatment that did not worsen after laser treatment. No cataracts attributable to laser therapy were seen during short-term (4-month) follow-up.

In this population of infants with threshold ROP treated with indirect diode laser therapy, only 5% of 61 treated eyes progressed beyond threshold disease. No complications occurred. These findings suggest that indirect diode laser therapy for ROP is an effective treatment to optimize short-term structural outcome.

Accepted for publication October 26, 1999.

Reprints: Mitchell H. DeJonge, MD, William Beaumont Hospital, 3601 W 13 Mile Rd, Royal Oak, MI 48073 (e-mail: mdejonge@beaumont.edu).

REFERENCES